Zealand Pharma A/s Stock
Price
Target price
€38.58
€38.58
-3.380%
-1.35
-3.380%
-
09:41 / Tradegate
WKN: A0YJW7 / Name: Zealand / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Zealand Pharma A/s Stock
Heavy losses for Zealand Pharma A/s today as the stock fell by -€1.350 (-3.380%).
So far the community has only identified positive things for Zealand Pharma A/s stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Zealand Pharma A/s in the next few years
Pros
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
S********** s********
Cons
?
G***** c******* t* c**********
?
B****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Zealand Pharma A/s vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Zealand Pharma A/s | -3.380% | 3.660% | 5.273% | -19.964% | -37.590% | 26.601% | 61.399% |
| Saniona AB | -1.180% | 5.333% | 4.682% | 51.341% | -38.217% | 72.993% | -23.745% |
| Actinium Pharmaceuticals Inc. | -2.040% | -8.005% | -8.641% | -39.280% | -34.300% | -87.609% | -86.328% |
| NanoViricides Inc. | -1.320% | 6.522% | 28.947% | 19.512% | 58.065% | 12.214% | -56.041% |
News
HICL Infrastructure Targets 10%+ Returns With Self-Funded Growth Strategy
Key Points
- Interested in HICL Infrastructure PLC? Here are five stocks we like better.
- HICL Infrastructure is targeting 10%+ medium-term total returns by shifting more of its portfolio toward
Why Rocket Lab Stock Went to the Moon Today
Rocket star Rocket Lab (NASDAQ: RKLB) is making headlines again this morning, after completing yet another satellite launch for Synspective over the weekend. (They also delayed a launch for iQPS,
A Weight-Loss Rival Just Crashed 23%. Why That's Great News for Eli Lilly and Novo Nordisk.
The GLP weight-loss space has become increasingly competitive as new players have entered what many believe is a game-changing new market that’s still in the early innings.
But getting in the game